Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 8/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932038 | 0.88 | BACE1 (1.00) | BACE1KCNH2BACE2APPKDM4C | |
| SCHEMBL932236 | 0.82 | BACE1 (0.53) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL931601 | 0.74 | BACE1 (0.50) | BACE1KCNH2BACE2APP | |
| SCHEMBL932165 | 0.70 | BACE1 (0.79) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL931947 | 0.70 | BACE1 (1.00) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932326 | 0.69 | BACE1 (0.56) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL931611 | 0.68 | BACE1 (0.68) | BACE1KCNH2BACE2 | |
| SCHEMBL932246 | 0.67 | BACE1 (1.00) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL18926490 | 0.66 | BACE1 (0.63) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932205 | 0.66 | BACE1 (0.61) | BACE1KCNH2BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |